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prescribed antibiotic preceded by amoxicillin (31%), 
and followed by amoxicillin/clavulanate (12%) and 
clarithromycin (7%). Efﬁcacy amongst comparators was
similar; although azithromycin treated patients had the
highest percentage of cures (86%) and fewest failures
(9%). Amoxicillin/clavulanate (83%) had the fewest
cures and clarithromycin had the most failures (11%).
Azithromycin was $35 more expensive than amoxicillin
with a total mean cost of approximately $141 compared
to clarithromycin and amoxicillin/clavulanate, which
were $80 and $89 more expensive than amoxicillin
($106), respectively. In contrast to amoxicillin/clavu-
lanate and clarithromycin, pharmacy claims accounted
for <50% of amoxicillin and azithromycin total costs.
CONCLUSIONS: With comparable efﬁcacy and resource
utilization advantages versus amoxicillin/clavulanate and
clarithromycin, this study suggests azithromycin was the
most cost-effective brand antibiotic.
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RSV is the most common cause of respiratory diseases in
children under age two worldwide. However few studies
have addressed the epidemiology and economic burden
of this infection in adults. The elderly, institutionalized
individuals and those with chronic cardiopulmonary
disease (COPD, asthma, CHF) are at high-risk for RSV
infection.
OBJECTIVES: To estimate the incidence of RSV infec-
tion, and describe healthcare resource use in a high-risk
adult population.
METHODS: A subset of the pharmetrics database (an
insurance administrative claims database) containing
records on 2.3 million patients from four large insurance
plans was utilized for this analysis. Adult subjects with
COPD, asthma or CHF claims in 1996 and 1997 were
enrolled and followed from January 1st 1998–May 31st
2001 (observation period) for new RSV diagnoses.
RESULTS: A total of 16,806 subjects (contributing
27,698.4 person-years) were studied. Sixty subjects with
RSV infection (RSV cohort) were identiﬁed during the
observation period. The incidence rate was 216.6
cases/100,000 person-years (95% CI 166.8–277.1). Of
the covariates of interest at enrollment (age, gender, other
comorbidity, steroid and oxygen use), only older age was
associated with RSV infection (P < 0.0001). The propor-
tion of subjects hospitalized for CHF/COPD/asthma was
higher in the RSV cohort after controlling for age, gender
and comorbidity (57% vs. 28%, P = 0.0005). A similar
difference was found for ICU admission (7% vs. 2%, 
P = 0.013). The median hospitalization cost in the RSV
cohort was $9,592.26, compared to $5,899.04 (P =
0.039). Outpatient visits and drug utilization were not
signiﬁcantly different between the groups.
CONCLUSIONS: This incidence rate may represent an
underestimation of the true RSV incidence as a result of
under-diagnosis in adults and lack of treatment options.
Nevertheless RSV infection in this population may repre-
sent an under appreciated cost burden to the healthcare
system. New diagnostic aids and treatment options are
needed to address this unmet medical need.
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While the hospitalization costs of severe sepsis have been
estimated, the long-term economic consequences of sepsis
survivors may be of greater importance to healthcare
decision-makers.
OBJECTIVES: The objective of this study is to estimate
and compare the long-term healthcare cost for patients
following discharge from a hospitalization for sepsis or
severe sepsis.
METHODS: This retrospective database study used
managed care claims data from 1995 to 1998 to identify
patients greater than 18 years of age with an ICD-9 code
indicating septicemia or bacteremia during a hospitaliza-
tion. Patients who experienced any signs of organ failure
during the index hospitalization as indicated by ICD-9
codes comprised the severe sepsis group; the remaining
patients comprised the sepsis group. The index hospital-
ization was deﬁned as the hospitalization containing the
ﬁrst sepsis or severe sepsis diagnosis during the above
timeframe. Patients were excluded if they did not have
any claims following hospital discharge. Log-transformed
monthly healthcare expenditures were analyzed using
analysis of variance. The propensity score method using
5 subclassiﬁcations was used to make both groups (sepsis
and severe sepsis) comparable, reducing the bias in the
analysis.
RESULTS: Of approximately 3 million members in the
database, 3,403 patients met the inclusion criteria with
2,666 (78.3%) in the sepsis group and 737 (21.7%) in
the severe sepsis group. The adjusted mean monthly cost
after discharge from the index hospitalization was
$496.63 (95%CI: $466.23–$529.01) for the sepsis group
and $571.29 (95%CI: $506.87–$643.89) for the severe
sepsis group. Severe sepsis patients were 15.0% (p =
0.043) more costly than the sepsis patients.
CONCLUSION: Interventions aimed at reducing the 
likelihood of disease progression from sepsis to severe
sepsis are likely to have beneﬁcial long-term economic
consequences for patients and healthcare systems.
